Cancer Drug's hidden vitamin drain: can a simple pill keep treatment on track?
NCT ID NCT04024254
Summary
This study looked at whether the cancer drug olaparib causes a folic acid (folate) deficiency in patients with advanced ovarian or breast cancer. Researchers wanted to see how often this happens and if giving patients a folic acid vitamin supplement could prevent the deficiency. Preventing this side effect is important because low folate can force doctors to reduce or stop the cancer treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Rush University Medical Center
Chicago, Illinois, 60612, United States
Conditions
Explore the condition pages connected to this study.